查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1523296

異位性皮膚炎市場報告：2030 年趨勢、預測與競爭分析

Atopic Dermatitis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

異位性皮膚炎的趨勢和預測

預計到 2030 年，全球異位性皮膚炎市場將達到約 233 億美元，2024 年至 2030 年複合年成長率為 9.4%。該市場的主要驅動力是技術的快速進步和資金籌措的增加，以及政府對研發支持的增加。全球異位性皮膚炎市場的未來看起來充滿希望，醫院藥房、零售藥房和線上藥房市場充滿機會。

異位性皮膚炎依部位分類

按藥物類別、給藥方法、分銷管道和地區提供全球異位性皮膚炎市場的預測。

異位性皮膚炎市場洞察

Lucintel 預測，由於人們對異位性皮膚炎治療方法的認知不斷提高，生物製藥將在預測期內實現最高成長。

由於異位性皮膚炎的高發生率，醫院藥局將繼續成為該市場的最大部分。

由於患者治療意識的提高以及該地區許多私人製造商的存在，預計北美在預測期內仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球異位性皮膚炎市場預計將達到 233 億美元。

Q2.市場成長預測是多少：

A2. 2024 年至 2030 年，全球異位性皮膚炎市場預計將以 9.4% 的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要促進因素是技術的快速進步和資金籌措的增加以及政府對研發的支持的增加。

Q4.市場的主要細分市場是：

A4. 異位性皮膚炎市場前景廣闊，醫院藥局、零售藥局和網路藥局市場充滿機會。

Q5.市場的主要企業是：

A5. 異位性皮膚炎領域的主要企業如下：

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測，由於人們對異位性皮膚炎治療方法的認知不斷提高，生物製藥預計將在預測期內實現最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於患者治療意識的提高以及該地區存在許多內部製造商，北美將在預測期內繼續成為最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球異位性皮膚炎市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球異位性皮膚炎市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物類別分類的異位性皮膚炎全球市場
    • PDE-4抑制劑
    • 皮質類固醇
    • 生物製藥
    • Calcineurin抑制劑
    • 其他
  • 依給藥方式分類的異位性皮膚炎全球市場
    • 局部的
    • 注射
    • 口服
  • 按分銷管道分類的全球異位性皮膚炎市場
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第4章 2018-2030年區域市場趨勢及預測分析

  • 按地區分類的全球異位性皮膚炎市場
  • 北美異位性皮膚炎市場
  • 歐洲異位性皮膚炎市場
  • 亞太地區異位性皮膚炎市場
  • 其他地區異位性皮膚炎市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
  • 全球異位性皮膚炎市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球異位性皮膚炎市場的產能
    • 全球異位性皮膚炎市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
簡介目錄

Atopic Dermatitis Trends and Forecast

The future of the global atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Atopic Dermatitis by Segment

The study includes a forecast for the global atopic dermatitis by drug class, mode of administration, distribution channel, and region.

Atopic Dermatitis Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • PDE-4 Inhibitor
  • Corticosteroids
  • Biologics
  • Calcineurin Inhibitors
  • Others

Atopic Dermatitis Market by Mode of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Topical
  • Injectable
  • Oral

Atopic Dermatitis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Atopic Dermatitis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Atopic Dermatitis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies atopic dermatitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the atopic dermatitis companies profiled in this report include-

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Atopic Dermatitis Market Insights

Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Within this market, hospital pharmacy will remain the largest segment due to notable prevalence of atopic dermatitis.

North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Features of the Global Atopic Dermatitis Market

Market Size Estimates: Atopic dermatitis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Atopic dermatitis market size by drug class, mode of administration, distribution channel, and region in terms of value ($B).

Regional Analysis: Atopic dermatitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, mode of administration, distribution channels, and regions for the atopic dermatitis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the atopic dermatitis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the atopic dermatitis market size?

Answer: The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030.

Q2. What is the growth forecast for atopic dermatitis market?

Answer: The global atopic dermatitis market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the atopic dermatitis market?

Answer: The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

Q4. What are the major segments for atopic dermatitis market?

Answer: The future of the atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

Q5. Who are the key atopic dermatitis market companies?

Answer: Some of the key atopic dermatitis companies are as follows:

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Q6. Which atopic dermatitis market segment will be the largest in future?

Answer: Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Q7. In atopic dermatitis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the atopic dermatitis market by drug class (PDE-4 inhibitor, corticosteroids, biologics, calcineurin inhibitors, and others), mode of administration (topical, injectable, and oral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Atopic Dermatitis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Atopic Dermatitis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Atopic Dermatitis Market by Drug Class
    • 3.3.1: PDE-4 Inhibitor
    • 3.3.2: Corticosteroids
    • 3.3.3: Biologics
    • 3.3.4: Calcineurin Inhibitors
    • 3.3.5: Others
  • 3.4: Global Atopic Dermatitis Market by Mode of Administration
    • 3.4.1: Topical
    • 3.4.2: Injectable
    • 3.4.3: Oral
  • 3.5: Global Atopic Dermatitis Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Atopic Dermatitis Market by Region
  • 4.2: North American Atopic Dermatitis Market
    • 4.2.1: North American Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.2.2: North American Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Atopic Dermatitis Market
    • 4.3.1: European Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.3.2: European Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Atopic Dermatitis Market
    • 4.4.1: APAC Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.4.2: APAC Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Atopic Dermatitis Market
    • 4.5.1: ROW Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.5.2: ROW Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Atopic Dermatitis Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Atopic Dermatitis Market by Mode of Administration
    • 6.1.3: Growth Opportunities for the Global Atopic Dermatitis Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Atopic Dermatitis Market by Region
  • 6.2: Emerging Trends in the Global Atopic Dermatitis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Atopic Dermatitis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Atopic Dermatitis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer
  • 7.2: AbbVie
  • 7.3: Incyte
  • 7.4: Novartis International
  • 7.5: Arcutis Biotherapeutics
  • 7.6: Bristol-Myers Squibb
  • 7.7: Regeneron Pharmaceuticals